Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.58 |
| ▸ | RET | P07949 | 2/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303673 | 1.00 | KDR (0.58) | KDRRETKDM1A | |
| SCHEMBL2451200 | 1.00 | KDR (0.58) | KDRRETKDM1A | |
| SCHEMBL2451007 | 0.88 | KDR (0.56) | KDRRET | |
| SCHEMBL2451006 | 0.88 | KDR (0.56) | KDRRET | |
| SCHEMBL12303659 | 0.85 | RET (0.63) | KDRRET | |
| SCHEMBL2451325 | 0.85 | RET (0.63) | KDRRET | |
| SCHEMBL2451323 | 0.85 | RET (0.63) | KDRRET | |
| SCHEMBL2453270 | 0.82 | KDM1A (0.47) | KDRKDM1A | |
| SCHEMBL12303627 | 0.81 | KDR (0.57) | KDRRET | |
| SCHEMBL2454020 | 0.81 | KDR (0.57) | KDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | claimed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | claimed |
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | claimed |
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | KDR 1975/4885RET 577/4885KDM1A 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.